IP Library Granted Patent US 12,171,978
Granted Patent B2
US 12,171,978 · App. 15/470,828 · Granted Dec 24, 2024

Medical container for accommodating protein solution formulation

Inventors: Hideaki Kiminami (Kanagawa, JP); Koji Nakamura (Tokyo, JP); Yoshihiko Abe (Kanagawa, JP); Shigeru Suzuki (Kanagawa, JP); Shigeru Tamatsukuri (Tokyo, JP)
Assignee: TERUMO KABUSHIKI KAISHA
A61M5/002A61J1/00A61J1/05A61J1/10A61J1/14A61K9/08A61K38/00A61K38/1816A61K39/395A61L2/07B65D75/326A61L2202/23
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,171,978
App. No.
15/470,828
Granted
Dec 24, 2024
Kind
B2
Abstract

A medical container for accommodating a protein solution formulation, in which the medical container is formed from a cycloolefin polymer, sterilized with high-pressure steam, and suppresses oxidization of amino acid residues in a protein in a protein solution formulation accommodated in the medical container.

Claims (23)

1. A product comprising:

a sterilized medical container that suppresses oxidization of amino acid residues, wherein the medical container consists essentially of a cycloolefin polymer and was sterilized with high-pressure steam; and

a stable protein solution accommodated in the medical container, wherein the protein solution comprises a protein selected from the group consisting of erythropoietin, a granulocyte colony-stimulating factor, thrombopoietin, a tissue plasminogen activator, a stem cell growth factor, an interferon, and an interleukin, and wherein 5% or less of methionine residues in the protein are oxidized immediately after accommodation in the medical container and for at least 4 weeks thereafter.

2. A product of claim 1 ,

wherein the medical container has a radical content of 2.2×10 15 radical/g or less as measured using an electron spin resonance spectrometer.

3. The product of claim 2 ,

wherein the medical container suppresses oxidization of amino acid residues in a protein in a protein solution formulation accommodated in the medical container.

4. The product according to claim 1 , wherein the cycloolefin polymer is a hydrogenated ring-opened polymer.

5. The product according to claim 2 , wherein the cycloolefin polymer is a hydrogenated ring-opened polymer.

6. The product according to claim 3 , wherein the cycloolefin polymer is a hydrogenated ring-opened polymer.

7. The product according to claim 1 , wherein the medical container is a syringe or cartridge.

8. The product according to claim 2 , wherein the medical container is a syringe or cartridge.

9. The product according to claim 3 , wherein the medical container is a syringe or cartridge.

10. The product according to claim 4 , wherein the medical container is a syringe or cartridge.

11. The product according to claim 1 , wherein the protein is erythropoietin.

12. The product according to claim 1 , wherein the medical container is a syringe.

13. A packaged product comprising:

the product of claim 1 ; and

a substantially oxygen-impermeable packaging material in which the product is sealed and packaged along with a deoxygenating agent.

14. The packaged product according to claim 13 , wherein an oxygen absorption capacity of the deoxygenating agent is one-fifth or more of a volume of a storage space within the packaging material.

15. The packaged product according to claim 13 , wherein the packaged product a blister package.

16. The packaged product according to claim 13 , wherein the substantially oxygen-impermeable packaging material has a light-blocking property.

17. The packaged product according to claim 13 , further comprising an outer packaging material in which the oxygen-impermeable packaging material is contained, the outer packaging material having a light-blocking property.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: KIMINAMI, HIDEAKI; NAKAMURA, KOJI; ABE, YOSHIHIKO; SUZUKI, SHIGERU; TAMATSUKURI, SHIGERU
To: TERUMO KABUSHIKI KAISHA
Reel/Frame 041757/0268 →
Priority Claims (1)
JP 2014-203616 · Oct 2, 2014 · national
Continuity (2)
Continuation PCTJP2015072633 · Aug 10, 2015
Related Publication 20170197024A1 · Jul 13, 2017